Journal Article
. 2019 Mar; 39(3):1447-1454.
doi: 10.21873/anticanres.13261.

One-step Nucleic Acid Amplification Can Identify Sentinel Node-negative Breast Cancer Patients With Excellent Prognosis

Kenzo Shimazu 1 Tomohiro Miyake 2 Jun Okuno 2 Yasuto Naoi 2 Tomonori Tanei 2 Masafumi Shimoda 2 Naofumi Kagara 2 Seung Jin Kim 2 Shinzaburo Noguchi 2 
  • PMID: 30842181
  •     1 citations


Background/Aim: One-step nucleic acid amplification (OSNA) is a newly developed procedure for detection of node metastasis by targeting CK19 mRNA. This study aimed to compare the prognosis of ER-positive/HER2-negative (ER+/HER2-) breast cancer patients with negative sentinel lymph node (SLN), as determined by OSNA with that determined by pathology.

Patients And Methods: A total of 508 patients who underwent breast surgery and SLN biopsy were enrolled. Of 263 patients with negative SLN by OSNA (osN0), 239 were treated with endocrine therapy alone (osN0-ET), and of 107 with negative SLN by pathology (pN0), 103 were treated with endocrine therapy alone (pN0-ET).

Results: Distant relapse-free survival (DRFS) of osN0-ET group (99.5% at 6 years) was significantly better (p=0.044) than that of pN0-ET group. Multivariate analysis revealed that osN0 was significantly associated (p=0.019) with favorable DRFS.

Conclusion: ER+/HER2- breast cancer patients with negative SLN by OSNA show an excellent prognosis with endocrine therapy alone.

Keywords: Breast cancer; one-step nucleic acid amplification; prognosis; sentinel lymph node.

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Systematic Review.